BUZZ-Viatris hits over a year low after weaker-than-expected earnings forecast

Updates

Shares of generic drugmaker Viatris VTRS.O fall as much as 22% to over a year low of $8.77

Stock last down 14% at $9.67 in afternoon trade

Company forecast 2025 revenue to be between $13.5 billion and $14 billion, below analysts' estimate of $14.27 billion — LSEG

Expects 2025 adj profit between $2.12/share and $2.26/share, compared with estimates of $2.59/share

VTRS says it estimates FDA action will negatively impact its 2025 total revenues by about $500 million and adjusted core earnings by roughly $385 million

Last year, FDA has restricted imports from Viatris' Indore facility in India due to regulatory violations

VTRS also reports fouth-quarter adj profit of 54 cents/share, below analysts' estimate of 57 cents/share

Posts quarterly sales of $3.52 billion, below analysts' est of $3.61 billion

VTRS gained 8.6% in 2024